248 related articles for article (PubMed ID: 27845263)
21. Amyloid beta peptide is elevated in osteoporotic bone tissues and enhances osteoclast function.
Li S; Liu B; Zhang L; Rong L
Bone; 2014 Apr; 61():164-75. PubMed ID: 24473375
[TBL] [Abstract][Full Text] [Related]
22. Bone resorptive activity of human peripheral blood mononuclear cells after fusion with polyethylene glycol.
Manrique E; Castillo LM; Lazala O; Guerrero CA; Acosta O
J Bone Miner Metab; 2017 Mar; 35(2):127-141. PubMed ID: 26969392
[TBL] [Abstract][Full Text] [Related]
23. Osteoclastic differentiation and resorption is modulated by bioactive metal ions Co2+, Cu2+ and Cr3+ incorporated into calcium phosphate bone cements.
Bernhardt A; Schamel M; Gbureck U; Gelinsky M
PLoS One; 2017; 12(8):e0182109. PubMed ID: 28763481
[TBL] [Abstract][Full Text] [Related]
24. Integration of osteoclastogenesis through addition of PBMCs in human osteochondral explants cultured ex vivo.
Cramer EEA; de Wildt BWM; Hendriks JGE; Ito K; Hofmann S
Bone; 2024 Jan; 178():116935. PubMed ID: 37852425
[TBL] [Abstract][Full Text] [Related]
25. Glucose-dependent insulinotropic polypeptide (GIP) dose-dependently reduces osteoclast differentiation and resorption.
Mabilleau G; Perrot R; Mieczkowska A; Boni S; Flatt PR; Irwin N; Chappard D
Bone; 2016 Oct; 91():102-12. PubMed ID: 27451082
[TBL] [Abstract][Full Text] [Related]
26. Curcumin inhibits osteoclastogenic potential in PBMCs from rheumatoid arthritis patients via the suppression of MAPK/RANK/c-Fos/NFATc1 signaling pathways.
Shang W; Zhao LJ; Dong XL; Zhao ZM; Li J; Zhang BB; Cai H
Mol Med Rep; 2016 Oct; 14(4):3620-6. PubMed ID: 27572279
[TBL] [Abstract][Full Text] [Related]
27. Apremilast inhibits inflammatory osteoclastogenesis.
Degboé Y; Sunzini F; Sood S; Bozec A; Sokolova MV; Zekovic A; McInnes IB; Schett G; Goodyear CS
Rheumatology (Oxford); 2021 Dec; 61(1):452-461. PubMed ID: 33788924
[TBL] [Abstract][Full Text] [Related]
28. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients.
Jobke B; Milovanovic P; Amling M; Busse B
Bone; 2014 Feb; 59():37-43. PubMed ID: 24211427
[TBL] [Abstract][Full Text] [Related]
29. Spontaneous osteoclast formation from peripheral blood mononuclear cells in postmenopausal osteoporosis.
D'Amelio P; Grimaldi A; Pescarmona GP; Tamone C; Roato I; Isaia G
FASEB J; 2005 Mar; 19(3):410-2. PubMed ID: 15611151
[TBL] [Abstract][Full Text] [Related]
30. Bone disease in nephropathic cystinosis is related to cystinosin-induced osteoclastic dysfunction.
Claramunt-Taberner D; Flammier S; Gaillard S; Cochat P; Peyruchaud O; Machuca-Gayet I; Bacchetta J
Nephrol Dial Transplant; 2018 Sep; 33(9):1525-1532. PubMed ID: 29365190
[TBL] [Abstract][Full Text] [Related]
31. In vitro method for the screening and monitoring of estrogen-deficiency osteoporosis by targeting peripheral circulating monocytes.
Salamanna F; Maglio M; Giavaresi G; Pagani S; Giardino R; Fini M
Age (Dordr); 2015 Aug; 37(4):9819. PubMed ID: 26250906
[TBL] [Abstract][Full Text] [Related]
32. The sample size required for intervention studies on fracture prevention can be decreased by using a bone resorption marker in the inclusion criteria: prospective study of a subset of the Nagano Cohort, on behalf of the Adequate Treatment of Osteoporosis (A-TOP) Research Group.
Shiraki M; Kuroda T; Nakamura T; Fukunaga M; Hosoi T; Orimo H; Makino K;
J Bone Miner Metab; 2006; 24(3):219-25. PubMed ID: 16622735
[TBL] [Abstract][Full Text] [Related]
33. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
Michael H; Härkönen PL; Väänänen HK; Hentunen TA
J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of bone turnover in postmenopause, vertebral fracture, and hip fracture using biochemical markers for bone formation and resorption.
Takahashi M; Kushida K; Hoshino H; Ohishi T; Inoue T
J Endocrinol Invest; 1997 Mar; 20(3):112-7. PubMed ID: 9186815
[TBL] [Abstract][Full Text] [Related]
35. Osteoclastogenesis in children with 21-hydroxylase deficiency on long-term glucocorticoid therapy: the role of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin imbalance.
Faienza MF; Brunetti G; Colucci S; Piacente L; Ciccarelli M; Giordani L; Del Vecchio GC; D'Amore M; Albanese L; Cavallo L; Grano M
J Clin Endocrinol Metab; 2009 Jul; 94(7):2269-76. PubMed ID: 19401376
[TBL] [Abstract][Full Text] [Related]
36. The degree of osteoporosis in patients with vertebral fracture and patients with hip fracture: relationship to incidence of vertebral fracture.
Takahashi M; Kushida K; Naitou K
J Bone Miner Metab; 1999; 17(3):187-94. PubMed ID: 10757678
[TBL] [Abstract][Full Text] [Related]
37. Osteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitro.
Heervä E; Peltonen S; Svedström E; Aro HT; Väänänen K; Peltonen J
Bone; 2012 Mar; 50(3):798-803. PubMed ID: 22226973
[TBL] [Abstract][Full Text] [Related]
38. The beneficial effect of icaritin on osteoporotic bone is dependent on the treatment initiation timing in adult ovariectomized rats.
Peng S; Zhang G; Zhang BT; Guo B; He Y; Bakker AJ; Pan X; Zhen W; Hung L; Qin L; Leung WN
Bone; 2013 Jul; 55(1):230-40. PubMed ID: 23486180
[TBL] [Abstract][Full Text] [Related]
39. Influence of glucocorticoids on human osteoclast generation and activity.
Sivagurunathan S; Muir MM; Brennan TC; Seale JP; Mason RS
J Bone Miner Res; 2005 Mar; 20(3):390-8. PubMed ID: 15746983
[TBL] [Abstract][Full Text] [Related]
40. MiR-503 regulates osteoclastogenesis via targeting RANK.
Chen C; Cheng P; Xie H; Zhou HD; Wu XP; Liao EY; Luo XH
J Bone Miner Res; 2014 Feb; 29(2):338-47. PubMed ID: 23821519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
